Depression experts question the effectiveness of a stress hormone drug Published on: 20 January 2016 Pioneering research by mood disorder experts at 缅北禁地 has questioned the effectiveness of a drug suggested to treat depression. It is well recognised that stress can lead to an episode of depressive illness and some patients have raised levels of the stress hormone, cortisol, in their body as an indication of the mental health condition. Now the largest study of its kind has shown that a drug that blocks production of stress hormone does not routinely help in treating depression. The findings have been published in the journal Lancet Psychiatry. The study examined the effect of metyrapone - a drug which blocks the production of cortisol - in patients that had not responded to at least two conventional antidepressant drugs. Findings reveal that common use of anti-cortisol drugs is ineffective for patients who have not responded to traditional treatments and there is a need to carry on searching for better treatment options to deal with the condition. Treatment of resistant depression , Reader in Clinical Psychopharmacology, was one of the leads of the three year study that was spearheaded by . He said: “Our research has shown that in the population of depressed patients studied, metyrapone is inadequate and therefore should not be routinely recommended as an option for treatment resistant depression. “We can’t rule out, however, that there might be some patients with particularly high levels of cortisol who might be helped by anti-cortisol treatment – but this needs to be specifically tested in a clinical trial.” Depression is a common mental health problem and people with the condition can experience intense anxiety, along with feeling of hopelessness and self-loathing. One in 10 people will be affected by depression in their lifetime. Experts from the Northern Centre for Mood Disorders at 缅北禁地 and Northumberland, Tyne and Wear NHS Foundation Trust joined forces with colleagues from the University of Manchester, Tees, Esk and Wear Valley NHS Foundation Trust, Bradford District Care NHS Foundation Trust and Leeds and York Partnership NHS Foundation Trust, to carry out the research. A total of 165 depressed patients, being treated by GPs or psychiatrists from sites in Northern England, were randomly allocated to a period of treatment with either metyrapone or a placebo (dummy tablet) in addition to their ongoing conventional antidepressants. The aim of the Antidepressant augmentation with metyrapone for treatment resistant depression study (The ADD Study) was to examine the efficacy, tolerability and safety of metyrapone as a realistic therapeutic option in everyday clinical practice. Researchers at the Northern Centre for Mood Disorders have previously shown in rats that raised stress hormones may reduce the effectiveness of antidepressants. This has led to a number of small studies using drugs that block the effect of cortisol or inhibit its production as treatments for depression. Some of these showed positive results. However, the ADD study questions the use of such treatments routinely in clinical practice. It also suggests that depression is more complex than simply being a consequence of high levels of stress hormone. Dr McAllister-Williams added: “While stress may well play a role in the development of depression in some individuals, using a drug to decrease the potential negative effects of stress hormones in those whose depression has not responded to conventional antidepressants does not work. “Our findings suggest that in people who have not responded to several conventional antidepressants and been depressed for some time, either stress plays less of a role in the development of their depression or these effects wears off over time.” Research challenges The research challenge now is to identify if different groups of depressed patients would respond to drugs acting on their stress hormone system, as well as identifying treatments targeting different systems within the brain for patients not responding to conventional antidepressants. The study was funded by the Efficacy and Mechanism Evaluation (EME) programme, a UK Medical Research Council and National Institute for Health Research partnership. 缅北禁地 Academic Health Partners - who carried out the ADD Study - is a collaboration of 缅北禁地, Northumberland, Tyne and Wear NHS Foundation Trust and 缅北禁地 Hospitals NHS Foundation Trust. 缅北禁地 and Northumberland, Tyne and Wear NHS Foundation Trust have come together to form the Northern Centre for Mood Disorders (NCMD). A key element of the NCMD is a large Research Register of both patients and healthy subjects who are willing to take part in research. NCMD is also developing a comprehensive educational portfolio aimed at healthcare professionals and provide training and support for those wishing to develop their research skills or pursue an academic career. Dr McAllister-Williams said: “NCMD will act as a focus for the development and implementation of cutting edge therapies. Our aim is to improve the care of patients across the North of England through research.” Reference Antidepressant augmentation with metyrapone for treatment resistant depression (The ADD Study): a double-blind, randomised, placebo controlled trial. McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HC, Haddad PM, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S, Siddiqi N, Sinha BN, Steen N, Wainwright J, Winter FH, Ferrier IN, Watson S; ADD Study Team. Lancet Psychiatry. 2015 Dec 22. pii: S2215-0366(15)00436-8. doi: 10.1016/S2215-0366(15)00436-8. [Epub ahead of print] Case study One man who knows the importance of research into depression is Paul Finkill. For a decade, the grandfather-of-one lived with the crippling mental illness and it affected all aspects of his life. Things became so serious that Paul felt he did not want to carry on and could not see a positive future as he struggled with severe anxiety attacks. Yet, after receiving the correct treatment, the 63-year-old now has his life firmly back on track and is enjoying spending time with his family and friends. Paul, of Gosforth, 缅北禁地, said he welcomes the 缅北禁地 Academic Health Partners’ study. He said: “The ADD Study is hugely important as it’s essential to gain a better understanding into the treatment options available to people with depression. “Sadly, depression is such a difficult condition to deal with and it’s an illness that seriously impacts on the patient and their family’s life. “The research that is being done in 缅北禁地 is offering hope to patients that positive things are being done to establish the best treatment options possible to alleviate the symptoms of depression.” Share: Latest News 缅北禁地 historians mark General Strike centenary To mark the 100th anniversary of the British General Strike and miners鈥� lock-out of 1926, historians at 缅北禁地 are organising a series of events on its enduring legacy. published on: 16 April 2026 Comment: NCP is in administration Writing for The Conversation, Erwei (David) Xiang discusses how some big companies like NCP are so dependent on debt that they can鈥檛 adjust to change. published on: 16 April 2026 缅北禁地 expert highlights climate crisis in a new film A leading 缅北禁地 climate scientist is featured in a new film about how the climate and nature breakdown will affect the UK. published on: 14 April 2026 Facts and figures
![缅北禁地 logo](/gomobileassets/img/logo.svg" "缅北禁地"){kind=logo}